We had visitors @moffittnews.bsky.social today!

In the second, Doris Hansen presents a matched real world analysis comparing cilta-cel to ide-cel. At Moffitt, we are mainly using cilta-cel now. 3/3

First, Ciara Freeman presents the new Arcellx/Kite BCMA CAR T data for myeloma. Looks to be the Goldilocks of CAR T - extremely effective but no cases of Parkinson’s or cranial nerve palsies to date with 150 pts treated. 2/3

Fascinating work by Bacchisio Ziccheddu and Francesco Maura (UMiami) outlining that tumor loss of MHC I (with resultant NK inhibition) associates with relapse after CAR T in patients treated by us at Moffitt. Suggests that CAR T needs to recruit other aspects of immunity to work!